Original-Research: Nynomic AG (von NuWays AG): BUY

dpa-AFX  | 
aufrufe Aufrufe: 34
A-
A+
Lesemodus
playAudio
playTeilen

Zeitungsständer (Symbolbild).
Zeitungsständer (Symbolbild). © Global_Pics / iStock Unreleased / Getty Images
^

Original-Research: Nynomic AG - from NuWays AG

11.05.2026 / 09:00 CET/CEST

Dissemination of a Research, transmitted by EQS News - a service of EQS

Group.

The issuer is solely responsible for the content of this research. The

result of this research does not constitute investment advice or an

invitation to conclude certain stock exchange transactions.


Classification of NuWays AG to Nynomic AG

Company Name: Nynomic AG

ISIN: DE000A0MSN11

Reason for the research: Update

Recommendation: BUY

Target price: EUR 25

Target price on sight of: 12 months

Last rating change:

Analyst: Christian Sandherr

Q1 prelims: Inflection point reached; PT Up

Q1 preliminary sales grew 8% yoy to EUR 22.3m, marking the first quarter with

top-line growth since Q1 2024. EBIT turned positive at EUR 0.1m versus EUR -0.9m

a year ago, supported by the improved top-line and confirming that the

NyFIT2025 efficiency program is translating into structural margin recovery.

The annualised savings of approximately EUR 5m are now visibly flowing through

the P&L, and with the group structure leaner and the cost base materially

reduced, the operative platform is well positioned to leverage revenue

growth into profitability at an accelerating rate through the year.

Order backlog/intake stand out. At the end of Q1, the order backlog stood at

EUR 55.6m, up 23% yoy, implying an order intake of EUR 32.9m (+80% yoy, +36%

qoq) with a book-to-bill ratio of 1.47x, the highest figure since 2022. A

particular driver of this were semiconductor gas analysis solutions. This

provides exceptional visibility for the remainder of the year, pointing

towards further accelerating sales as reflected by the confirmed FY26 sales

guidance of EUR 100-105m (eNuW: EUR 100m).

On the margin trajectory, the path to our FY26e EBIT margin estimate of 6.7%

looks well supported; FY guidance 6-8%. With the NyFIT savings fully

annualised, H2 revenue scaling (higher margin semi orders turning into

sales) and the structurally high gross margin of Nynomic's business

providing significant operating leverage, the bulk of profitability delivery

should be H2-weighted.

LayTec amongst structural growth drivers. The subsidiary's real-time

metrology systems for semiconductor manufacturing (deployed in MOCVD

equipment including Aixtron's) allow precise in-situ process control for GaN

and InP wafer production. In fact, Aixtron's recent Q1 release was marked by

30% order intake growth and positive remarks regarding accelerating demand.

As energy efficiency, power density and data centre interconnect

requirements drive structurally rising demand for compound semiconductors,

the need for additional production equipment should remain high. LayTec

should be well positioned to benefit from this.

Importantly, LayTey is only one of the group's growth drivers. tec5 supplies

spectrometer modules to semiconductor metrology OEMs and participates in the

pharma PAT wave (real-time inline monitoring of pharmaceutical

manufacturing), Avantes is the world's number two in fibre-optic

spectrometers with growing exposure to semiconductor and smart farming

applications, and m-u-t is pushing into semiconductor particle analytics via

a new partnership with BRAVE Analytics.

After two transition years, the combination of a recovering demand base, a

leaner cost structure, strong order intake and structural mid-term drivers

make for a compelling setup. We hence confirm our BUY rating and increase

our PT to EUR 25 (old: EUR 21) based on DCF as we raise our margin estimates

going forward.

You can download the research here:

https://eqs-cockpit.com/c/fncls.ssp?u=9309c5246fb86cc84f63b7ae8b88d4da

For additional information visit our website:

https://www.nuways-ag.com/research

Contact for questions:

NuWays AG - Equity Research

Web: www.nuways-ag.com

Email: research@nuways-ag.com

LinkedIn: https://www.linkedin.com/company/nuwaysag

Adresse: Mittelweg 16-17, 20148 Hamburg, Germany

Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss

bestimmter Börsengeschäfte.

Offenlegung möglicher Interessenkonflikte nach § 85 WpHG beim oben

analysierten Unternehmen befindet sich in der vollständigen Analyse.


The EQS Distribution Services include Regulatory Announcements,

Financial/Corporate News and Press Releases.

View original content:

https://eqs-news.com/?origin_id=b9fe3c30-4d03-11f1-8534-027f3c38b923&lang=en


2324686 11.05.2026 CET/CEST

°


Werte aus dem Artikel:
Nynomic Aktie 21,10 € -5,80%


Dein Kommentar zum Artikel im Forum

Jetzt anmelden und diskutieren Registrieren Login

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.

Themen im Trend